Frank Richard

Title: The Innovative Contributions of Frank Richard

Introduction

Frank Richard, an accomplished inventor based in Kronberg, Germany, has made significant strides in the field of biotechnology. With two notable patents to his name, Richard continues to push the boundaries of innovation within the pharmaceutical industry.

Latest Patents

Richard's latest patents illustrate his expertise in chromatographic purification and ultrafiltration processes. His first patent, titled "Procedure for the chromatographic purification of insulins," details an improved method utilizing a pressure-stable organic polymeric chromatography material as a stationary phase. The innovative mobile phase includes a water-miscible organic solvent and a buffer substance, with a pH range between 7 and 11. This advancement is significant for the efficient purification of insulins, impacting medical therapies.

The second patent, "Ultrafiltration process for desalination and concentration of a peptide," focuses on the ultrafiltration of peptides in cell-free fermentation mediums. This invention leverages a membrane with a cut-off molecular weight significantly greater than that of the peptide, effectively retaining the peptide while providing desalination and concentration. The temperature during this process is ideally maintained between 5 to 15 degrees Celsius, ensuring optimal results. Remarkably, the permeate flow rate can range from 10 to 35 liters per square meter per hour, contributing to more effective peptide purification processes.

Career Highlights

Frank Richard is associated with Aventis Pharma Deutschland GmbH, a company known for its commitment to advancing pharmaceuticals through innovative research and development. Throughout his career, Richard has been pivotal in driving research initiatives that address critical needs in biopharmaceutical manufacturing.

Collaborations

Richard has collaborated with esteemed colleagues in his field, including Jorg Moller and Werner Sievers. Together, they have explored various avenues for enhancing biotechnological processes, fostering an environment of innovation and excellence. Their combined efforts contribute to the overall growth and success of Aventis Pharma.

Conclusion

In conclusion, Frank Richard’s innovative mindset and dedication to biotechnological advancements have led to significant developments in the purification processes of insulins and peptides. His contributions not only showcase his skills as an inventor but also underscore the importance of collaboration within the research community. Frank Richard remains a key player in pushing the frontiers of scientific progress in the pharmaceutical sector.